The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the ...

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug ...